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Abstract
Background: After its introduction, laparoscopic cholecystectomy rapidly expanded around the world
and was accepted the procedure of choice by consensus. However, analysis of evidence shows no
difference regarding primary outcome measures between laparoscopic and small-incision
cholecystectomy. In absence of clear clinical benefit it may be interesting to focus on the resource use
associated with the available techniques, a secondary outcome measure. This study focuses on a difference
in costs between laparoscopic and small-incision cholecystectomy from a societal perspective with
emphasis on internal validity and generalisability
Methods: A blinded randomized single-centre trial was conducted in a general teaching hospital in The
Netherlands. Patients with reasonable to good health diagnosed with symptomatic cholecystolithiasis
scheduled for cholecystectomy were included. Patients were randomized between laparoscopic and small-
incision cholecystectomy. Total costs were analyzed from a societal perspective.
Results: Operative costs were higher in the laparoscopic group using reusable laparoscopic instruments
(difference 203 euro; 95% confidence interval 147 to 259 euro). There were no significant differences in
the other direct cost categories (outpatient clinic and admittance related costs), indirect costs, and total
costs. More than 60% of costs in employed patients were caused by sick leave.
Conclusion: Based on differences in costs, small-incision cholecystectomy seems to be the preferred
operative technique over the laparoscopic technique both from a hospital and societal cost perspective.
Sick leave associated with convalescence after cholecystectomy in employed patients results in
considerable costs to society.
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Background
Langenbuch's classical cholecystectomy has been the gold
standard for over a century [1]. Since the mid 1970's sur-
geons began shortening their incisions because of a pre-
sumed quicker convalescence [2,3]. Soon thereafter,
laparoscopic cholecystectomy (LC) was introduced, and
rapidly expanded around the world [4]. The popularity of
this procedure was partly based on an appealing techno-
logical innovation as well as industry driven motives and
not primarily a result of an evidence-based approach [5].
Analysis of evidence in Cochrane reviews shows no differ-
ence regarding primary outcome measures (mortality and
complications) between the three operative techniques of
cholecystectomy (open, small-incision and laparoscopic)
[6-8]. In absence of clear clinical benefit based on these
meta-analyses it may be interesting to focus on the
resource use associated with the available techniques. We
performed a single blind randomized clinical trial focus-
ing on a secondary outcome: costs. In a previous paper we
emphasized intrinsic validity of this trial, proved repro-
ducibility of results from other trials and showed general-
isability in a general teaching hospital.[9]
The costs of LC and small-incision cholecystectomy (SIC)
have been compared in six randomized trials. [10-15]
These available studies are inconsistent in outcome and
conclusions, use different perspectives and most of the tri-
als suffer methodological shortcomings.
The research question is whether there is a difference in
costs from a societal perspective between small-incision
and laparoscopic cholecystectomy using a blind rand-
omized approach. In a detailed cost analysis attention has
to be paid to both direct and indirect costs as well as the
perspective of the analysis. Furthermore, cost prices,
budget prices and tariffs have to be distinguished.
Methods
In meta-analyses we found no major differences in clinical
outcome measures (mortality, complications, conver-
sions, hospital stay, and convalescence) between LC and
SIC for patients with symptomatic cholecystolithiasis.[8]
We also found no differences considering pulmonary
function, health status, and cosmesis. [16,17] Costs are a
secondary outcome measure and ultimately may be a
decisional factor. This paper focuses on cost-minimiza-
tion analysis.
Medical Ethics Committee approval for this single-centre
trial was obtained in September 2000. Between January
2001 and January 2004, all patients referred to our surgi-
cal outpatient's clinic with symptomatic cholecystolithia-
sis (confirmed by ultrasonography) were considered for
inclusion in this study.
Inclusion- and exclusion criteria
Inclusion criteria were male or female patients with symp-
tomatic cholecystolithiasis, aged 18 years or older at
recruitment, reasonable to good health (ASA I or II), no
known relevant allergies, and a signed informed consent
letter.
Exclusion criteria were age younger than 18 years,
choledocholithiasis (icterus, acholic faeces and/or biliru-
bine of twice normal range), cholangitis, known preg-
nancy, moderate to severe systemic disease (ASA III and
higher), known cirrhosis of the liver, history of abdominal
malignancy, previous upper abdominal surgery (preclud-
ing a laparoscopic approach), psychiatric disease, or a rea-
sons (e.g. lack of knowledge of the Dutch language) that
might make follow-up or completion of questionnaires
unreliable.
Obesity was not an exclusion criterion. Recovery after suc-
cessful endoscopic treatment of choledocholithiasis was
not a contra-indication. Acute cholecystitis was excluded.
Randomization
A random number table was used for generation of the
allocation sequence [18] and the allocation concealment
was guaranteed by using sealed envelopes. Patients were
randomized after induction of anesthesia. An employee of
the secretary office opened an envelope. Details were
recorded in a case record form. Otherwise the procedure
was recorded as 'trial cholecystectomy'.
Surgical procedures
All patients had a standard anesthesia regime. Premedica-
tion, medications for induction and continuation of
anesthesia, as well as respiration during surgery were
standardized. Residents (from 2nd year on) performed
most of the operations. In case of technical difficulties
either trial technique could be converted to open chole-
cystectomy (OC). Wounds were covered with standard
wound dressings.[19] In this way blinding of patients,
nurses, and ward physicians was achieved. Postoperative
analgesics and medication for nausea were standardized.
Open introduction was performed in all laparoscopic
cholecystectomies. Pneumoperitoneum was created with
an intra-abdominal pressure up to 12 mmHg. Three tro-
cars for instruments were inserted. The dissection of the
cystic artery and cystic duct, identifying Calot's triangle,
was performed using a three points 'flag' technique [20]
The cystic duct and artery were clipped and transected. All
instruments were reusable.
In concordance with literature a cut-off point of 8 cm was
used to differentiate between SIC and OC.[14,19,21-26]
The incision was placed over the musculus rectusTrials 2009, 10:80 http://www.trialsjournal.com/content/10/1/80
Page 3 of 12
(page number not for citation purposes)
abdominis. No special equipment was used. Access to the
peritoneum was obtained by a 'muscle splitting' tech-
nique. The gallbladder was dissected by a 'fundus-first'
technique. The cystic duct and artery were ligated and the
gallbladder was removed. Posterior and anterior fascias
were closed separately. If the length of the incision
exceeded 8 cm, the operation was considered to be a con-
version to OC.
Postoperative protocol
Early oral intake and mobilization were encouraged.
Patients left the hospital as soon as they were able to do
so. Incidental 'social' reasons for lengthening of hospital
stay (by a few days) were accepted. Hospital stay was
defined as the number of postoperative nights in hospital.
For logistic reasons, we were not able to blind the surgeon
during follow-up. Follow-up was standardized after 2
weeks, 6 weeks and 3 months. Patients were encouraged
to resume work as soon as possible.
Analysis and sample size
In meta-analyses no differences in patient-relevant out-
comes appear to be present between these two techniques.
Assuming no differences in primary outcome measures,
sample size calculation was based on anticipated differ-
ences of costs. The direct costs of the first 50 patients in the
trial were calculated so as to estimate the likely range of
differences in costs and their standard deviations. On this
basis, we estimated that 120 patients per group would be
needed to detect a difference of 10% in direct costs using
an α of 0.05 and a β of 0.9.
Analyzing differences in costs due to complications
between both techniques would require another sample
size including thousands of patients in order to possibly
find significant results. Consequently, differences in com-
plication costs were therefore not statistically tested in our
study. However, these costs were reported to illustrate
their impact on total costs.
Statistics
All data were stored in a case record form (Access®) based
on a patient-linked trial registration number. A double
data entry was performed. Comparisons were made on an
intention to treat basis. Calculations were made using
SPSS 11.0®.
The chi-square test was used for dichotomous outcome.
Normality of data was checked using the Kolmogorov-
Smirnov test. [27] Levene's test was used for checking
equality of variances. When the condition of normality
and equal variances was met, the t-test for independent
data was used; otherwise the nonparametric Mann-Whit-
ney U test for independent data was used.
Methods of cost analysis
As cost items that are equally present in both groups do
not contribute to differences, it can be argued that these
can be left out of consideration. On the other hand all
costs contribute to the total amount and the incremental
value. Therefore, we strived for reporting costs in detail.
[28] For each cost item, hospital costs, overhead costs and
consultants' costs were included if appropriate (Table 1).
All costs were calculated in euros (2004). All direct medi-
cal costs were summarized in different categories includ-
ing costs due to complications (admittance, operative,
outpatients' clinic, and complications).
As there are no relevant or significant differences in clini-
cal outcome [8,16] or quality-of-life [17], a cost-minimi-
zation analysis seems most appropriate. Afterwards,
differences in costs can be balanced with other (thus far
unknown) differences in outcome.
In evaluating costs, it is important to be complete in
accounting for all items.[29] Therefore, in general a soci-
etal perspective is recommended. [30-32] In a societal per-
spective all costs are included in the analysis (patient,
hospital and losses in production), irrespective of the
stakeholder incurring the costs or who benefits from treat-
ment. Moreover, today's limited health care budgets war-
rant proper economic evaluation of treatments, especially
when incidences and impact on economy are high (like in
symptomatic cholecystolithiasis).
Definitions of cost categories
Direct medical costs
costs resulting from outpatient clinic, hospital admit-
tance, surgery, complications, etcetera.
Direct non-medical costs
costs arising from outside health care immediately related
to treatment (e.g. traveling costs from patients). The prob-
lem is that it is very difficult to estimate these costs accu-
rately in all patients. We assume that these costs are equal
for both groups. Moreover, since the vast majority of
patients have an uncomplicated recovery, these costs are
assumed not to contribute importantly to total costs.
Indirect non-medical costs
costs due to loss of productivity related to employment
status of patients. These costs arise from loss of productiv-
ity caused by sick leave, disabled for work or mortality. We
decided to use the friction cost method. [31-36]
Tariffs, cost prices, budget prices and overhead costs
In cost assessments tariffs, cost prices and budget prices
have to be distinguished. Tariffs are costs that are calcu-Trials 2009, 10:80 http://www.trialsjournal.com/content/10/1/80
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lated for insurance companies. Tariffs are nearly always
different from real costs. Budget prices on the other hand
are figures used for internal (hospital) calculations, and
do not reflect real costs either. Cost prices are real costs for
procedures and are usually not used in hospital adminis-
trations. These cost prices can be calculated but are some-
times difficult to retrieve.
Apart from these differences there are costs for deprecia-
tion and interest. Different methods are used and no uni-
form guidelines exist how to estimate these overhead
costs, neither do arguments exist that one method is supe-
rior over the other. In our hospital a percentage incremen-
tal value is added to every cost price. We applied this
method in our study.
Description of procedures and measurement of resources
In this cost-minimization analysis, all resources were pro-
spectively recorded. A visit to the general practitioner,
diagnostic examinations, and costs due to preoperative
outpatient clinic visits were counted. Hospital stay was
counted as the number of overnights stay. Medication use
is included in admittance cost prices. Operative costs and
the costs of anesthesiologists were calculated according to
operating room occupancy. Standard materials and
equipment used in the operating room including costs
associated with cleaning and sterilisation are included in
hospital costs for surgery. The costs of the surgeon and res-
ident were calculated from the time of incision to last
suture. In laparoscopic instruments extra laparoscopy-
specific materials like clips and endobags were calculated,
but monitor, gass-insufflator, and camera were not calcu-
lated as these were considered present. In the small-inci-
sion procedure no extra equipment other than standard
instruments is needed. In follow-up the time of the sur-
geon was calculated. Finally, if complications occurred, all
extra costs were included. Costs of consultants were calcu-
lated using the national agreed honorarium (140 euro per
hour) (Table 1).
Sensitivity analyses
Several sensitivity analyses were performed to yield an
impression of the effect of changes on total costs. Varia-
bles were considered if the costs were appreciable and a
change in the costs of the variable could be possible and
clinically relevant:
1. The influence of the use of disposable instead of
reusable laparoscopic instruments on total costs.
2. Influence of reduction of time back-to-work by one
week on total costs.
3. Influence of the reduction of hospital stay by one
night on total costs.
Table 1: List of cost items used in calculations of total costs. For 
each cost item hospital costs, overhead costs and consultants 
costs are included if appropriate.
Item
Preoperative General practioner
First visit to outpatient clinic (20 min)
X-thorax *
ECG
Blood examinations
Consultation pulmonologist (36 min)
Consultation cardiologist (22.65 min)
Consultation internist (30 min)
ERCP (30 min)
Ultrasound * (10 min)
Operative Hospital operating room per minute
Anaesthesiologist per minute#
Surgeon per minute
Surgical resident per minute
Laparoscopic instruments - reusable
Laparoscopic instruments - disposable
Admittance Ultrasound localization of gallbladder
Blood gas analysis (Åstrup)
Spirometry analysis
One night hospital stay
One night medium care (including intensivist)
Intensive care (with mechanical breathing)
Intensive care (without mechanical breathing)
Pathology examination
Follow-up Outpatients visit (10 min)
Complications Ultrasound drainage (10 min)
Blood cultureTrials 2009, 10:80 http://www.trialsjournal.com/content/10/1/80
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Results
All trial patients were included and operated between Jan-
uary 2001 and March 2004. Leaving unwilling and
excluded patients out of consideration, 366 patients visit-
ing the outpatient clinic of the hospital for symptomatic
cholecystolithiasis fulfilled the inclusion criteria and were
initially included in the trial. A total of 102 patients were
not randomized for a variety of reasons (Figure 1). [37]
After randomizing 264 patients, another 7 patients were
excluded for the following reasons: unwilling to continue
in the trial (n = 2), intra-operative suspicion of malig-
nancy (n = 2), transfer to a non-surgical ward (n = 1),
inadvertent participation in multiple trials (n = 1), and
inadequate Dutch language skills (n = 1). A total of 257
patients were left for analysis (LC:120 and SIC:137).
The two treatment groups did not differ regarding age, sex,
body mass index (BMI), and American Society of Anesthe-
siologists (ASA) classification (table 2). None of the 257
patients were lost to follow-up and resources of all
patients could be determined.
The numbers of converted procedures, hospital stay, the
number of residents performing the procedure, and the
number of intra-operative and postoperative complica-
tions were not significantly different. Operative time was
significantly shorter in the small-incision group (differ-
ence 11 minutes, 95% confidence interval (CI) 6 to 17
minutes; p < 0.001) (table 3). The total costs for both
treatment groups including all 257 patients are summa-
rized (Table 4).
There is an important difference in direct costs. The differ-
ence is caused by differences in costs due to complications
and rendering total costs in favor of the laparoscopic pro-
cedure.
The difference in operation theatre cost is in favor of the
SIC group however. Operation theatre costs are over 23%
more expensive in the LC group compared to the SIC
group (LC: 1112 euro compared to SIC: 901 euro; differ-
ence 211 euro, p < 0.001). Indirect costs are higher in the
laparoscopic group.
Data of costs are non-Gaussian distributed, importantly
influenced by one extreme outlier. Therefore, although
intention-to-treat is violated, the results excluding one
outlier in each group are also shown (Table 4). Results in
the cost categories admittance and outpatients' clinic do
not change. There still is a difference in operation theatre
costs in favor of the SIC group (difference 203 euro; 95%
CI 147 to 259 euros). In the total costs, there is a differ-
ence in favor of the SIC group. All patients were operated
using reusable laparoscopic instruments and costs were
calculated accordingly.
In order to be able to compare uncomplicated LC and SIC
procedures, costs were also calculated excluding all com-
plicated cases. There still are differences present in the
operation theatre related costs (difference 199 euro; 95%
CI 139 to 259 euro; p < 0.001) and in total direct costs
(difference 139 euro; 95% CI 42 to 237 euro; p = 0.006).
No significant differences were observed in other direct
cost categories, indirect costs, and total costs.
In order to estimate the influence of indirect costs on total
costs we performed calculations only including employed
patients (Table 5). Indirect costs appear to amount over
60% of total costs in both groups.
We performed a sensitivity analysis assuming the use of
disposable instead of reusable laparoscopic instruments.
Calculations show increase of operation costs resulting in
differences of approximately 960 euro in favor of the SIC
group (95% CI 912 to 1024 euro; p < 0.001).
A sensitivity analysis assuming a decrease in work leave by
1 week for the employed patients (n = 101) in this trial
results in savings of 82790 euro. In another sensitivity
Blood transfusion
Urologist outpatients visit (30 min)
Gastroscopy (30 min)
MRCP *
CT abdomen *
CT thorax *
CT angiography *
CT cerebrum *
MR cerebrum *
Re-laparotomy
Emergency department visit
Ultrasound duplex
* Time spend by radiologists at diagnostic procedures was estimated 
at 10 minutes
# In our hospital anaesthesiologists are responsible for two operations 
at a time. Therefore, 140 euro (per hour) was calculated for two 
operations resulting in 1.17 euro per minute per operation.
Time spend by consultants (for diagnostic procedures) in brackets.
Table 1: List of cost items used in calculations of total costs. For 
each cost item hospital costs, overhead costs and consultants 
costs are included if appropriate. (Continued)Trials 2009, 10:80 http://www.trialsjournal.com/content/10/1/80
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Revised consort statement diagram showing the flow of participants through each stage of the randomized trial [37] Figure 1
Revised consort statement diagram showing the flow of participants through each stage of the randomized 
trial [37].
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Table 2: Patient characteristics.
Laparoscopic cholecystectomy
(n = 120)
Small-incision cholecystectomy
(n = 137)
Statistical analysis
Male/Female 31/89 30/107 p = 0.459
Age
mean (SD) 48.4 (14.1) 48.5 (14.0) p = 0.974
median (range) 49 (17-77) 48 (18-80)
BMI
mean (SD) 27.5 (4.8) 27.9 (4.6) p = 0.500
median (range) 26.8 (18.5-45.9) 27.2 (18.0-43.3)
ASA
I 82 (68.3%) 91 (66.4%) p = 0.855
II 38 (31.7%) 46 (33.6%)
Table 3: Comparison of clinical results.
Laparoscopic cholecystectomy
(n = 120)
Small-incision cholecystectomy
(n = 137)
Statistical analysis
Mortality 0 0
Complications 21 16 p = 0.119
intra-operative 5 3 p = 0.363
postoperative 16 13 p = 0.331
Failed symptom relief 11 (9.2%) 14 (10.2%) p = 0.777
Operative time (min):
mean (SD) 71.9 (25.8) 60.4 (18.3) p < 0.001
median (range) 68.5 (26-215) 60.0 (29-105)
Conversion rate 14 (11.7%) 22 (16.1%) p = 0.312
Operative team:
surgeon-resident 15 (12.5%) 21 (15.3%) p = 0.515
resident-surgeon 84 (70.0%) 100 (73.0%) p = 0.596
resident-resident 21 (17.5%) 18 (13.1%) p = 0.331
Hospital stay*
mean (SD) 2.4 (4.6) 3.1 (12.4) p = 0.560
median (range) 1 (1 - 36) 2 (1 - 144)
Hospital stay* (without 1 extreme value)
mean (SD)
2.1 (3.4) 2.0 (2.4) p = 0.877
Number of patients with:
1 night stay postoperative 67 (55.8%) 62 (45.3%) p = 0.091
2 nights stay postoperative 38 (31.7% 56 (40.9%) p = 0.127
* hospital stay: in postoperative nightsTrials 2009, 10:80 http://www.trialsjournal.com/content/10/1/80
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analysis assuming a decrease in hospital stay by 1 night for
the employed patients (n = 101) in this trial results in sav-
ings of 22980 euro.
Discussion
When no differences in primary outcomes are found, con-
sequently, several secondary outcome measures like oper-
ative time, hospital stay, and time to recovery as well as
costs can be chosen as focus for a trial. Most of these sec-
ondary outcome measures are incorporated in a total cost
assessment. Our cost analyses show that SIC is more
expensive compared to LC when all patients are included
(intention to treat, Table 4). Excluding one outlier from
analyses in each group, total costs per patient are higher in
Table 4: Overview of costs with all patients included and without one extreme value in each group (in euro). 
Laparoscopic
cholecystectomy
Small-incision
cholecystectomy
Difference in costs
(per patient)
significance
All patients included 
(intention-to-treat)
(n = 120) (n = 137)
Direct costs 305760 452654
(per patient)
- Outpatients clinic related 2548 3304 -756 P = 0,006*
(per patient)
- Operation theatre related
(per patient)
- Admittance related 54293 62627
(per patient) 452 457 -5 P = 0.640
- Complications related
Indirect costs 133406 123404
(per patient) 1112 901 211 P < 0.001*
Total costs 67972 81707
(per patient)
566 596 -30 P = 0.342
50089 184917
(n = 50) (n = 51)
172005 155024
3440 3040 400 P = 0.315
477765 607678
3981 4436 -454 P = 0.737
Without one outlier in each 
group
(n = 119) (n = 136)
Direct 272584 282683
(per patient) 2291 2079 212 P = 0.006*
- Outpatient clinic related 53980 62273
(per patient) 454 458 -4 P = 0.669
- Operation theatre related 130796 121856 203 P < 0.001*
(per patient) 1099 896
- Admittance related 67421 81131
(per patient) 567 597 -30 P = 0.346
- Complications related 20388 17423
Indirect (n = 50) (n = 51)
172005 155024
(per patient) 3440 3040 400 P = 0.315
Total costs 444589 437706
(per patient) 3736 3218 518 P = 0.034*
* significant difference
Negative differences in costs favour the laparoscopic procedure and positive differences in costs favour the small-incision technique.Trials 2009, 10:80 http://www.trialsjournal.com/content/10/1/80
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the LC group (p = 0.034). This difference is caused by a
difference in operative costs (difference 203 euro; 95% CI
147 to 259 euro; p < 0.001) and a difference in indirect
costs (p = 0.315). When all complicated cases are
excluded, direct costs (p = 0.006) and operative costs (199
euro, p < 0.001) per patient remain higher in the LC group
(using reusable laparoscopic instruments).
The problem in reporting costs are non-Gaussian distribu-
tions. Following intention-to-treat principles, compli-
cated cases should be included to obtain an objective
impression of absolute costs. Using means results in a
biased impression of falsely increased measures as a con-
sequence of skewed data, while using medians would
ignore complicated cases since in cholecystectomy about
80% of operations are uneventful procedures (Table 4). In
our trial one extreme outlier occurred. Differences in tech-
niques have to be distinguished from random variations.
Meta-analyses demonstrate no differences in complica-
tions between laparoscopic and small-incision cholecys-
tectomy. We therefore believe that differences in
complication costs should be considered random varia-
tions. Moreover, our trial was not powered to detect differ-
ences in complication costs and these results should be
considered a spurious finding and should therefore not be
statistically tested at all. Reporting costs excluding one
outlier in each group might therefore be more correct as it
incorporates complication costs but prohibits distortion
of total costs by random extreme outliers.
There are several problems in analyzing and pooling cost
results from different studies. First of all, costs are reported
in different ways including different cost items. A second
problem is that different points of views are taken. These
different perspectives make comparison of studies diffi-
cult. A third problem is the difference in validity of the
cost assessments, defined by the details in which costs are
calculated. More detailed analyses are known for more
reliable estimates, while less detailed studies cause severe
bias.[28,29] A fourth problem in comparing studies is
that there may be considerable differences in local costs.
Specific items in cost analyses differ from one country or
even setting to another. A fifth and probably most impor-
tant problem are cultural differences. There are wide vari-
ations in convalescence (and return to work) between
different cultures depending on a multitude of causes, like
social security and cultural habits.[38,39] As multiple fac-
tors cause heterogeneity, pooling results seems inappro-
priate and one may only draw general conclusions from
individual studies.
In literature six trials report costs and lack of methodolog-
ical quality was present in several trials.[10,12,14,40] In
some trials methodology of cost assessment was very lim-
ited described.[12,40] Outpatients' costs [11,12] and indi-
rect costs.[10-12,14] are excluded in several studies
making overall (societal) comparison of techniques
incomplete. Retrospective analyses [14] or expert settings
[11,14] raise questions on reliability and generalisability.
Table 5: Overview of costs with employed patients only (in euro). 
Laparoscopic 
cholecystectomy
(n = 120)
Small-incision 
cholecystectomy
(n = 137)
Difference in costs
(per patient)
significance
60 and older 26 26
Employed (male/female) 50 51
Unemployed/unknown 44 60
Employed n = 50 n = 51
Direct (37.7%) (38.4%)
104003 96454
(per patient) 2080 1891 189 P = 0.055
Indirect (62.3%) (61.6%)
172005 155024
(per patient) 3440 3040 400 P = 0.315
- Average period before return to 
work (in weeks (SD)):
4.2 (2.3) 3.7 (2.0) P = 0.298
Total 276008 251477
(per patient) 5520 4931 589 P = 0.179
Total indirect costs: 327029 euro (n = 101)
Average period before return to work: 4.0 (SD: 2.2) weeks
Average indirect costs per patient per week: 820 euro
Negative differences in costs favour the laparoscopic procedure and positive differences in costs favour the small-incision technique.Trials 2009, 10:80 http://www.trialsjournal.com/content/10/1/80
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In our trial surgical residents performed 86% of the oper-
ations.
The trials by Calvert and Nilsson are high quality tri-
als.[11,13] Unfortunately, outpatients' clinic costs and
indirect costs are not included in the trial by Calvert.[11]
Additionally, median hospital stay and estimated opera-
tive time (instead of individual data) are used for calcula-
tions. They concluded that hospital costs using the
laparoscopic technique were 29% higher.[11] The trial by
Nilsson is a high quality multi-centre trial. However,
standardization of procedures is less biased and more uni-
form in a single-centre trial compared to a multi-centre
trial. Costs are reported in medians (ignoring outliers and
complications). This study found lower direct costs and
higher indirect costs for the SIC group.[13]
Some conclusions of differences in costs were based on
differences in hospital stay [10] or convalescence.[13,14]
However, in meta-analysis no differences were found in
hospital stay and convalescence between both tech-
niques.[8] The differences in indirect costs in our trial
should be considered as random variations caused by ran-
dom differences in age and sex between both groups in
the employed patients: calculated friction costs per hour
per employee are higher for male and for higher aged
employees.
Remarkably, the trials with lack in methodological or cost
assessment quality [10,14,40] favor the laparoscopic tech-
nique, while the trials with high methodological quality
or more detailed cost assessments [11,13] favor the small-
incision technique. This linkage between unclear/inade-
quate methodological quality to significant overestima-
tion of beneficial effects and underreporting of adverse
effects is in concordance with other studies.[8,41,42]
Different parties have different interests in cost analyses.
Though, all perspectives belong to our society. Advantages
of a certain therapy in a societal perspective should be
given more importance compared to other perspectives
not including all cost categories. It provides the most com-
prehensive assessment and is most relevant for national
policy decisions. Implementation at a local level, how-
ever, may require to also taking into account a hospital
perspective as financial consequences will become visible.
Feasibility of ambulatory cholecystectomy [43,44] and
the wide range in return to work from a few days to 12
weeks raises questions on potential savings. Possibilities
for future savings by reduction of hospital stay (direct
costs), irrespective of the operating technique for chole-
cystectomy, were compared to savings by reduction of sick
leave (indirect costs). Assuming 21000 cholecystectomies
in the Netherlands, reducing hospital stay by one night
(50%) in every patient would result in potential savings of
4.8 million euro in the Netherlands annually. Assuming
that 50% of the cholecystectomy patients are employed
(Table 5), reducing sick leave by one week (25%) in every
employed patient would lead to savings of 8.6 million
euro on a national basis annually. Based on these hypo-
thetical figures it seems easier to achieve savings by earlier
return to work instead of reducing hospital stay. Moreo-
ver, as more than 60% of costs of employed patients are
caused by sick leave it is more logical to focus on this cost
category.
Assuming 21000 cholecystectomies in the Netherlands
and an employment ratio of 50%, calculations of sensitiv-
ity analyses on hypothetical savings were performed con-
sidering change in policy from disposable to reusable
laparoscopic instruments, change from LC to SIC, or
reducing sick leave by one week. As a result savings of
approximately 16 million, 4.2 million and 8.6 million
euro respectively are possible on a national basis annu-
ally. However, conclusions have to be careful since calcu-
lations are hypothetical.
Conclusion
In this single-centre trial with representative results and
emphasis on methodological quality LC appears more
costly: the procedural costs surpass those of SIC (and use
of disposable instruments would only further increase this
difference). Thus SIC is the preferred operative technique
over LC both from a hospital and societal cost perspective.
Sick leave associated with convalescence after surgery
results in considerable costs to society especially in the
employed patient.
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